Opinion|Videos|October 7, 2024
Current Treatment Options for Dravet Syndrome
Author(s)M. Scott Perry, MD
Key Takeaways
- The primary treatment goal for Dravet syndrome is reducing seizure frequency and severity while improving quality of life and minimizing side effects.
- Initial treatments for Dravet syndrome include valproate and clobazam, which are effective in managing seizures.
The panelist discusses how the goal of Dravet syndrome treatment is to reduce seizure frequency and severity, typically starting with initial treatments like valproate and clobazam and potentially escalating to combination therapies including options such as cannabidiol, with the overall aim of improving patients’ quality of life and developmental outcomes
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the goal of treatment for Dravet syndrome?
- Please describe the recommended initial treatments for Dravet syndrome.
- Valproate
- Clobazam
- Please describe the recommended initial treatments for Dravet syndrome.
- Please describe treatment options that are available as escalation therapy in combination with initial treatments for Dravet syndrome.
- Stiripentol
- Cannabidiol
- Fenfluramine
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.
An epileptologist at Cleveland Clinic discussed findings from a recently published study of lifestyle interventions in epilepsy and why these approaches should complement rather than replace antiseizure medications.
Pediatric epilepsy care goes beyond seizures, addressing mental health, learning needs, coordinated referrals, equitable access, and smoother transition to adult services.
Here's some of what is coming soon to NeurologyLive® this week.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]
Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.
At a NeurologyLive Clinical Forum in Phoenix, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how a lack of adult neuro-oncology infrastructure is shaping how NF1-associated plexiform neurofibromas get recognized, referred, and treated.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 NIMBLE Trial: Cemdisiran Efficacy and Safety Results in gMG
2
FDA Grants Fast Track Status to FRP-003 for Long COVID Ahead of Phase 2 Study
3
Headlining Current Advances and Challenges in Multiple Sclerosis Care
4
Optimizing and Personalizing Treatment in Generalized Myasthenia Gravis
5